The collaboration brings AI-trained breast cancer detection software to SimonMed’s nationwide network, aiming to support earlier, more precise diagnoses.
SimonMed Imaging has announced a partnership with Lunit, a company specializing in artificial intelligence (AI)-driven cancer diagnostics and therapeutics, to bring AI-powered breast cancer detection to patients nationwide.
SimonMed selected Lunit INSIGHT DBT, in combination with Volpara Analytics, to power its personalized breast cancer detection service, designed to provide patients with a precise, highly personalized, and data-driven screening experience.
“This is more than just an upgrade—it’s an important step forward for our patients’ health,” says Sean Raj, chief innovation officer at SimonMed Imaging and fellow of The Society of Breast Imaging, in a release. “We’ve evaluated a range of AI technologies, and Lunit’s performance, speed, and clinical validation stood above the rest. This partnership enables us to offer the most precise and personalized mammogram experience to date—and when paired with our board-certified breast radiologists, we believe it offers the most advanced mammogram available today.”
Lunit INSIGHT DBT is trained on millions of images and engineered to detect even the most subtle signs of breast cancer, improving both sensitivity and specificity. Integrated into SimonMed’s national network of over 170 accredited centers and supported by more than 200 subspecialty-trained radiologists, this AI solution is designed to help ensure earlier detection, faster turnaround times, and actionable insights for patients.
“This is one of the most advanced AI solutions we’ve ever adopted,” says John Simon, MD, founder and CEO of SimonMed Imaging, in a release. “It reflects our unwavering commitment to providing every patient we see with the most accurate, affordable, and proactive care possible.”
Photo caption: Lunit INSIGHT DBT
File photo
